Creative Medical Technology Holdings, Inc. announced positive top line pilot study results for the StemSpine® procedure using AlloStem™ to treat chronic lower back pain. The data demonstrated significant efficacy and no serious adverse events using the StemSpine® ultrasound guided non-surgical procedure for treating chronic lower back pain. The StemSpine® procedure using AlloStem™ resulted in a greater than 90% reduction in narcotic usage, greater than 80% reduction in pain score, and greater than 50% reduction in the Oswestry Score in the treated patients.

No patients required re-dosage or surgical intervention at the primary end point of six months and there were no safety related concerns. StemSpine® using AlloStem™ is a patented procedure that utilizes an "off the shelf, ready-to-use" universal and proprietary allogenic (donor) cell developed by the Company and trademarked as AlloStem™. The patent issued to StemSpine® includes both the use of autologous (from the patient) and allogenic (universal donor) cells.

In February 2023, the Company reported positive three-year follow-up data for its StemSpine® pilot study using autologous cells to treat chronic lower back pain.